DC
RARE icon

Diametric Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

Diametric Capital’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,021
Closed -$288K – 158
2021
Q2 		$288K Buy
+3,021
New +$315K 0.21% 101

Other funds holding RARE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Diametric Capital's RARE Position: Q3 2021 in Review

Diametric Capital sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2021, closing a stake of 3,021 shares — an estimated $288K sold.

Diametric Capital first reported a position in RARE in Q2 2021 and held it in 1 quarter. The position peaked at $288K in Q2 2021. 221 funds tracked by Wall St. Rank hold RARE as of Q3 2021.

  • Diametric Capital reported no remaining Ultragenyx Pharmaceutical position as of Q3 2021 after selling out during the quarter.
  • Diametric Capital sold 3,021 Ultragenyx Pharmaceutical shares in Q3 2021, an estimated $288K.
  • Diametric Capital first reported a position in Ultragenyx Pharmaceutical in Q2 2021 and held it in 1 quarter.
  • Diametric Capital's Ultragenyx Pharmaceutical position peaked at $288K in Q2 2021.
  • 221 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2021.

Based on Diametric Capital's 13F filing for Q3 2021, filed 15 Nov 2021.